Tag - ATHE

Developments

USPTO grants Alterity new composition of matter patent

Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that the United States Patent and Trademark Office (USPTO) has granted a new composition of matter patent for the company’s lead clinical asset, ATH434, an...

August 12, 2026

Executive Moves

Alterity names Dr. Daniel O. Claassen chief medical advisor

Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that Daniel O. Claassen, MD, PhD, has been appointed chief medical advisor. In addition to this role, Dr. Claassen will retain his academic appointment as...

March 4, 2026

Developments

Alterity underscores published data on role of iron in neurodegenerative diseases

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has highlighted a peer-reviewed article published in Metallomics, emphasizing the significance of iron and iron-targeting agents, such as the company’s ATH434, in treating...

November 6, 2024

Tag - ATHE

USPTO grants Alterity new composition of matter patent

Alterity names Dr. Daniel O. Claassen chief medical advisor

Alterity underscores published data on role of iron in neurodegenerative diseases

Subscribe